Skip to main content

ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.

Publication ,  Journal Article
Buller, CE; Fu, Y; Mahaffey, KW; Todaro, TG; Adams, P; Westerhout, CM; White, HD; van 't Hof, AWJ; Van de Werf, FJ; Wagner, GS; Granger, CB ...
Published in: Circulation
September 23, 2008

BACKGROUND: Primary percutaneous coronary angioplasty is an effective and widely adopted treatment for acute myocardial infarction. A simple method of determining prognosis after primary percutaneous coronary intervention (PCI) would facilitate appropriate care and expedite hospital discharge. Thus, we determined the prognostic importance of various measures of ST-segment-elevation recovery after primary PCI in a large, contemporary cohort of patients with ST-elevation myocardial infarction. METHODS AND RESULTS: We analyzed ECG data describing the magnitude and extent of ST-segment elevation and deviation before and early after (ie, 30 minutes) primary PCI in the study cohort of 4866 subjects with electrocardiographically high-risk ST-elevation myocardial infarction enrolled in the Assessment of PEXelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Associations among 6 methods for calculating ST-segment recovery, biomarker estimates of infarct size (ie, peak creatine kinase, creatine kinase-MB, and troponin I and T), and prespecified clinical outcomes (ie, rates of 90-day death and 90-day death, heart failure, or shock) were examined. All ST-segment-recovery methods provided strong prognostic information regarding clinical outcomes. A simple ST-segment-recovery method of residual ST-segment elevation measurement in the most affected lead on the post-PCI ECG performed as well as complex methods that required comparison of pre- and post-PCI ECGs or calculation of summed ST-segment deviation in multiple leads (ie, worst-lead residual ST elevation: adjusted hazard ratio for 90-day death rate [reference <1 mm]: 1 to <2 mm, 1.23 [95% CI 0.74 to 2.03]; > or =2 mm, 2.22 [95% CI 1.35 to 3.65], corrected c-index=0.832; 90-day death/congestive heart failure/shock [reference <1 mm]: 1 to <2 mm, 1.55 [95% CI 1.06 to 2.26]; > or =2 mm, 2.33 [95% CI 1.59 to 3.41], corrected c-index=0.802). Biomarker estimates of infarct size declined in association with enhanced ST-segment recovery. CONCLUSIONS: An ECG performed early after primary PCI is a simple, widely available, inexpensive, and powerful prognostic tool applicable to patients with ST-elevation myocardial infarction.

Duke Scholars

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

September 23, 2008

Volume

118

Issue

13

Start / End Page

1335 / 1346

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Single-Chain Antibodies
  • Shock, Cardiogenic
  • Recovery of Function
  • Prognosis
  • Predictive Value of Tests
  • Myocardial Infarction
  • Multivariate Analysis
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Buller, C. E., Fu, Y., Mahaffey, K. W., Todaro, T. G., Adams, P., Westerhout, C. M., … Armstrong, P. W. (2008). ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Circulation, 118(13), 1335–1346. https://doi.org/10.1161/CIRCULATIONAHA.108.767772
Buller, Christopher E., Yuling Fu, Kenneth W. Mahaffey, Thomas G. Todaro, Peter Adams, Cynthia M. Westerhout, Harvey D. White, et al. “ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.Circulation 118, no. 13 (September 23, 2008): 1335–46. https://doi.org/10.1161/CIRCULATIONAHA.108.767772.
Buller, Christopher E., et al. “ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.Circulation, vol. 118, no. 13, Sept. 2008, pp. 1335–46. Pubmed, doi:10.1161/CIRCULATIONAHA.108.767772.
Buller CE, Fu Y, Mahaffey KW, Todaro TG, Adams P, Westerhout CM, White HD, van ’t Hof AWJ, Van de Werf FJ, Wagner GS, Granger CB, Armstrong PW. ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Circulation. 2008 Sep 23;118(13):1335–1346.

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

September 23, 2008

Volume

118

Issue

13

Start / End Page

1335 / 1346

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Single-Chain Antibodies
  • Shock, Cardiogenic
  • Recovery of Function
  • Prognosis
  • Predictive Value of Tests
  • Myocardial Infarction
  • Multivariate Analysis
  • Middle Aged
  • Male